Director/PDMR Shareholding

RNS Number : 5974D

AstraZeneca PLC

31 March 2014

 



Transaction by Person Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

On 28 March 2014, Pascal Soriot, a Director of AstraZeneca PLC, was granted awards over the Company's ordinary shares under the terms of the AstraZeneca Investment Plan (AZIP), the AstraZeneca Performance Share Plan (AZPSP) and the AstraZeneca Deferred Bonus Plan (AZDBP) as detailed below.

Name	Shares awarded under AZIP	Shares awarded under AZPSP	Shares awarded under AZDBP	Award price per share
Pascal Soriot	20,677	124,066	15,966	3904p

The AZIP award is subject to a four-year performance period (1 January 2014 to 31 December 2017) and a subsequent four-year holding period (1 January 2018 to 31 December 2021).

The AZPSP award is subject to a three-year performance period (1 January 2014 to 31 December 2016).

The AZDBP award is subject to a three-year holding period (28 March 2014 to 27 March 2017).

A summary of these plans and information about the performance measures that relate to the AZIP and AZPSP awards is set out in the Directors' Remuneration Report in the AstraZeneca Annual Report and Form 20-F Information 2013 which is available on the Company's website www.astrazeneca.com.

As a result of these awards, Mr Soriot has an interest in 572,626 ordinary shares which represents approximately 0.05% of the Company's issued ordinary capital.

A C N Kemp

Company Secretary

31 March 2014

 

END

 

 

RDSUAVARSWAOOAR